Discover Guideview's Pharmaceutical articles! Stay informed about the latest news, policies, and scientific insights relevant to the pharmaceutical industry.
Global Biopharma Layoffs April 2026Layoffs
Layoff
Novo Nordisk
BioNTechGlobal Biopharma companies including Novo Nordisk, IO Biotech, and BioNTech announce workforce reductions in April 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
BMS Full Year 2025 Financial ReportBMS
Financial statementsBristol Myers Squibb reports 2025 results with stable revenue, a sharp rebound in profitability, strong growth from new products, and resilient Eliquis sales reaching $14.4 billion despite patent pressures.
GSK Full Year 2025 Financial ReportGSK
Financial statementsGSK reported £32.7B revenue in 2025, up 4% YoY, driven by specialty medicines and vaccines. Core profit rose 7%, with strong R&D pipeline and steady global growth supporting 2026 outlook.
Merck Full Year 2025 Financial ReportMerck
Financial statementsMerck's 2025 performance shows 1% revenue growth, driven by strong sales of KEYTRUDA, new products like WINREVAIR, and growth in animal health. The company maintains cautious optimism for 2026 amid challenges like patent cliffs and currency fluctuations.
Eli Lilly Full Year 2025 Financial ReportEli Lilly
Financial statementsEli Lilly's 2025 results show a 45% revenue increase to $65.2B, driven by Mounjaro and Zepbound sales. With strong growth in profits and an optimistic 2026 outlook, the company continues to lead in metabolic diseases and oncology treatments.
Amgen Full Year 2025 Financial ReportAmgen
Financial statementsAmgen's 2025 revenue rose 10%, reaching $36.75B, driven by strong product sales and innovation. The company projects continued growth in 2026, with a focus on R&D, cost control, and shareholder returns.